tirzepatide trials once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Overview of the SURPASS clinical

obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition , such as high blood pressure, type 2 diabetes, or sleep apnoea

The shortest usable gap is exactly 2 days (48 hours)

Again, thinking about the risk-benefit ratio can help

[104] [105] In 1998, the company dedicated new laboratories for clinical research at the Indiana University Medical Center in Indianapolis

Lessai de phase 2, paru dans le New England Journal of Medicine en 2023, a document une perte de poids moyenne de 24,2 % du poids corporel sur 48 semaines chez des adultes obses ou en surpoids

The authors acknowledged certain study limitations and emphasized that these findings underscore the need for patient-centered nutritional guidance, potentially involving Registered Dietitian Nutritionists, to optimize health outcomes and address identified dietary education gaps